Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A Study

被引：10
|
作者：
Pratz, Keith W.
DiNardo, Courtney D.
Selleslag, Dominik
Li, Junmin
Yamamoto, Kazuhito
Konopleva, Marina
McDonald, Andrew
Babu, Sunil
Stevens, Don A.
Kantarjian, Hagop M.
Traina, Fabiola
Venditti, Adriano
Mayer, Jiri
Montez, Melissa
Ramsingh, Giridharan
Jin, Huan
Ainsworth, William
Duan, Yinghui
Svensson, Anders Erik
Werner, Michael
Potluri, Jalaja
Jonas, Brian A.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134832
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy
    Short, Nicholas J.
    Sedarati, Farhad
    Zhao, Dan
    Tsukurov, Olga
    Friedlander, Sharon
    Faller, Douglas V.
    BLOOD, 2020, 136
  • [22] Molecular characterization of clinical response in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib plus azacitidine compared to placebo plus azacitidine.
    De Botton, Stephane
    Choe, Sung
    Marchione, Dylan M.
    Montesinos, Pau
    Recher, Christian
    Polo, Susana Vives
    Zarzycka, Ewa
    Wang, Jianxiang
    Bertani, Giambattista
    Heuser, Michael
    Calado, Rodrigo T.
    Schuh, Andre C.
    Yeh, Su-Peng
    Hui, Jianan
    Pandya, Shuchi Sumant
    Gianolio, Diego A.
    Daigle, Scott
    Dinardo, Courtney Denton
    Dohner, Hartmut
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] Hematologic improvements with ivosidenib plus azacitidine compared to placebo plus azacitidine in patients with newly diagnosed acute myeloid leukemia.
    Dohner, Hartmut
    Montesinos, Pau
    Polo, Susana Vives
    Zarzycka, Ewa
    Wang, Jianxiang
    Bertani, Giambattista
    Heuser, Michael
    Calado, Rodrigo T.
    Schuh, Andre C.
    Yeh, Su-Peng
    Burguera, Adolfo de la Fuente
    Cerchione, Claudio
    Daigle, Scott
    Hui, Jianan
    Pandya, Shuchi Sumant
    Gianolio, Diego A.
    Recher, Christian
    De Botton, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study
    Garcia-Manero, Guillermo
    Abaza, Yasmin
    Takahashi, Koichi
    Medeiros, Bruno C.
    Arellano, Martha
    Khaled, Samer K.
    Patnaik, Mrinal
    Odenike, Olatoyosi
    Sayar, Hamid
    Tummala, Mohan
    Patel, Prapti
    Maness-Harris, Lori
    Stuart, Robert
    Traer, Elie
    Karamlou, Kasra
    Yacoub, Abdulraheem
    Ghalie, Richard
    Giorgino, Ruben
    Atallah, Ehab
    BLOOD ADVANCES, 2019, 3 (04) : 508 - 518
  • [25] Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia
    Xu, Xuezhu
    Liu, Rui
    Chen, Hongli
    Yang, Ruoyu
    Gao, Gongzhizi
    He, Aili
    Wang, Fangxia
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2025, 16
  • [26] Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemia
    Liu, Qingyang
    Yang, Jingjing
    Lv, Lei
    Zhang, Xiawei
    Li, Meng
    Xu, Lingmin
    Huang, Sai
    Jing, Yu
    Dou, Liping
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [27] Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib plus azacitidine compared to placebo plus azacitidine.
    De Botton, Stephane
    Montesinos, Pau
    Polo, Susana Vives
    Zarzycka, Ewa
    Wang, Jianxiang
    Riva, Marta
    Heuser, Michael
    Calado, Rodrigo T.
    Schuh, Andre C.
    Yeh, Su-Peng
    Hui, Jianan
    Gianolio, Diego A.
    Patel, Prapti Arvind
    Recher, Christian
    Dohner, Hartmut
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] Updated efficacy and safety data from the AGILE study in patients with newly-diagnosed acute myeloid leukemia treated with ivosidenib plus azacitidine compared to placebo plus azacitidine
    Heuser, M.
    Montesinos, P.
    Vives, Polo S.
    Zarzycka, E.
    Wang, J.
    Riva, M.
    Calado, R. T.
    Schuh, A. C.
    Yeh, S. -P
    Hui, J.
    Gianolio, D. A.
    Patel, P.
    Recher, C.
    de Botton, S.
    Doehner, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 95 - 95
  • [29] Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment
    Ikezoe, Takayuki
    Usuki, Kensuke
    Aida, Kensuke
    Hatayama, Tomoyoshi
    Shirahase, Toru
    Yamauchi, Takahiro
    CANCER SCIENCE, 2023, 114 (03) : 1037 - 1044
  • [30] Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax plus Hypomethylating Agent
    Gangat, Naseema
    Elbeih, Azeem
    Ghosoun, Nour
    Mccullough, Kristen
    Aperna, Fnu
    Johnson, Isla M.
    Abdelmagid, Maymona
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede H.
    Elliott, Michelle
    Mangaonkar, Abhishek
    Matin, Aasiya
    Saliba, Antoine N.
    Torghabeh, Mehrdad Hefazi
    Litzow, Mark R.
    Hogan, William
    Shah, Mithun
    Patnaik, Mrinal M.
    Pardanani, Animesh
    Badar, Talha
    Murthy, Hemant
    Foran, James
    Palmer, Jeanne
    Sproat, Lisa
    Khera, Nandita
    Yi, Cecilia Arana
    Yates, Samuel
    Sneider, Abigail
    Dworkin, Emily
    Patel, Anand A.
    Bazinet, Alexandre
    Senapati, Jayastu
    Bataller, Alex
    Dinardo, Courtney
    Kadia, Tapan
    Tefferi, Ayalew
    AMERICAN JOURNAL OF HEMATOLOGY, 2025, 100 (02) : 260 - 271
12345